Duloxetine
Product Images NDC 53002-1503

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 53002-1503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier plot showing the proportion of patients with relapse over time in days from randomization. The graph compares relapse rates between placebo and Duloxetine treatments, with Duloxetine showing a consistently lower proportion of relapse compared to placebo across the 200-day period.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo treatment with Duloxetine at 60/120 mg once daily, indicating higher percentages of patient improvement with Duloxetine across a range of pain improvement levels.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier plot comparing the proportion of patients with relapse over time (days) between Duloxetine treatment and placebo. The x-axis shows time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. Duloxetine shows a lower relapse proportion compared to placebo over the study period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo groups, illustrating trends in patient pain improvement across different doses and placebo.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The vertical axis represents the percentage of patients improved, and the horizontal axis represents percent improvement in pain, showing that both Duloxetine doses outperform placebo over the pain improvement range.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, with the Duloxetine groups generally showing higher patient improvement percentages than placebo across different levels of pain improvement.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg, 60 mg, and 120 mg doses, once daily, and placebo. The graph shows three separate lines for the Duloxetine doses and one for placebo, with the y-axis representing the percentage of patients improved and the x-axis showing the percent improvement in pain from baseline.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The horizontal axis shows percent improvement in pain, while the vertical axis represents the percentage of patients improved. The graph shows two plotted lines with Duloxetine generally showing higher improvement percentages than placebo across the range.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing placebo and Duloxetine 60 mg once daily in terms of percentage of patients improved by percent improvement in pain from baseline. The x-axis represents percent improvement in pain (≥0 to 100), and the y-axis shows the percentage of patients improved (0 to 100%). Duloxetine demonstrates higher patient improvement percentages across most improvement levels compared to placebo.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride, showing its molecular arrangement including a naphthyl group, thiophene ring, and amine hydrochloride moiety.*

FDA Label Image

Label Image (Lbl530021503)

Duloxetine 20mg delayed-release capsules packaging label from RPK Pharmaceuticals, Inc. The label indicates a count of 30 capsules with directions to take one capsule daily or as directed. The label features standard prescription information including lot number, expiration date, and barcodes, along with designated spaces for clinic and patient details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.